Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958467 | 0.86 | LRRK2 (0.55) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL15651089 | 0.85 | LRRK2 (0.55) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL19227479 | 0.83 | TLR9 (0.60) | LRRK2ALDH1A1POLBKDM4ETRPV6 | |
| SCHEMBL23997105 | 0.83 | LRRK2 (0.56) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL22280202 | 0.83 | TRPV6 (0.56) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL21738213 | 0.83 | LRRK2 (0.53) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL21738212 | 0.83 | LRRK2 (0.53) | LRRK2ALDH1A1POLBCYP2C19KDM4E | |
| SCHEMBL17689131 | 0.81 | HPGD (0.71) | ALDH1A1POLBCYP2C19KDM4ELMNA | |
| SCHEMBL23997104 | 0.80 | L3MBTL3 (0.51) | LRRK2ALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL23997108 | 0.76 | ALDH1A1 (0.52) | ALDH1A1POLBCYP2C19KDM4ETRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, GDI2 | LRRK2 1/4885ALDH1A1 2073/4885POLB 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.